CAMKK2 and male breast carcinoma: Furthermore, small molecule inhibitors are available for a number of the 14 genes represented in the classifier, such as CAMKK2 (STO-609)48, CAPN949, BACE250, and TNFSF11 (aka RANKL)51, and future studies could further elucidate whether these inhibitors may be applicable in the treatment of male breast cancer.